References
- Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342. https://doi.org/10.1038/nature01658
- Choi, H.K., Kang, H.R., Jung, E., Kim, T.E., Lin, J.J., and Lee, S.Y. (2013). Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. Cell Res. 23, 524-536. https://doi.org/10.1038/cr.2013.33
- Dougall, W.C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M.E., Maliszewski, C.R., et al. (1999). RANK is essential for osteoclast and lymph node development. Genes. Dev. 13, 2412-2424. https://doi.org/10.1101/gad.13.18.2412
- Erbagci, A.B., Araz, M., Erbagci, A., Tarakcioglu, M., and Namiduru, E.S. (2002). Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin. Biochem. 35, 263-268. https://doi.org/10.1016/S0009-9120(02)00305-3
- Ferron, M., Wei, J., Yoshizawa, T., Del Fattore, A., DePinho, R.A., Teti, A., Ducy, P., and Karsenty, G. (2010). Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142, 296-308. https://doi.org/10.1016/j.cell.2010.06.003
- Fleischmann, A., Hafezi, F., Elliott, C., Reme, C.E., Ruther, U., and Wagner, E.F. (2000). Fra-1 replaces c-Fos-dependent functions in mice. Genes. Dev. 14, 2695-2700. https://doi.org/10.1101/gad.187900
- Fulzele, K., DiGirolamo, D.J., Liu, Z., Xu, J., Messina, J.L., and Clemens, T.L. (2007). Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 282, 25649-25658. https://doi.org/10.1074/jbc.M700651200
- Fulzele, K., Riddle, R.C., DiGirolamo, D.J., Cao, X., Wan, C., Chen, D., Faugere, M.C., Aja, S., Hussain, M.A., Bruning, J.C., et al. (2010). Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309-319. https://doi.org/10.1016/j.cell.2010.06.002
- Harada, S., and Rodan, G.A. (2003). Control of osteoblast function and regulation of bone mass. Nature 423, 349-355. https://doi.org/10.1038/nature01660
- Hemingway, F., Taylor, R., Knowles, H.J., Athanasou, N.A. (2011). RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 48, 938-944. https://doi.org/10.1016/j.bone.2010.12.023
- Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., Tan, H.L., Elliott, G., Kelley, M.J., Sarosi, I., et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U.S.A. 96, 3540-3545. https://doi.org/10.1073/pnas.96.7.3540
- Itonaga, I., Sabokbar, A., Sun, S.G., et al. (2004). Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 34, 57-64. https://doi.org/10.1016/j.bone.2003.08.008
- Isaia, G.C., Ardissone, P., Di Stefano, M., Ferrari, D., Martina, V., Porta, M., Tagliabue, M., and Molinatti, G.M. (1999). Bone metabolism in type 2 diabetes mellitus. Acta. Diabetol. 36, 35-38. https://doi.org/10.1007/s005920050142
- Kemink, S.A., Hermus, A.R., Swinkels, L.M., Lutterman, J.A., and Smals, A.G. (2000). Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J. Endocrinol. Invest. 23, 295-303. https://doi.org/10.1007/BF03343726
- Kim, H.S. and Lee, N.K. (2014). Gene expression profiling in osteoclast precursors by insulin using microarray analysis. Mol. Cells 37, 827-832. https://doi.org/10.14348/molcells.2014.0223
- Kim, K., Lee, S.H., Ha Kim, J., Choi, Y., and Kim, N. (2008). NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol. Endocrinol. 22, 176-185. https://doi.org/10.1210/me.2007-0237
- Kudo, O., Sabokbar, A., Pocock, A., Itonaga, I., Fujikawa, Y., Athanasou, N.A. (2003). Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32,1-7. https://doi.org/10.1016/S8756-3282(02)00915-8
- Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176. https://doi.org/10.1016/S0092-8674(00)81569-X
- Lee, N.K. (2010). Molecular Understanding of Osteoclast Differentiation and Physiology. EnM. 25, 264-269.
- Lee, J.Y., and Lee, N.K. (2014) Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation. Life sci. 114, 57-61. https://doi.org/10.1016/j.lfs.2014.07.006
- Lee, S.H., Rho, J., Jeong, D., Sul, J.Y., Kim, T., Kim, N., Kang, J.S., Miyamoto, T., Suda, T., Lee, S.K., et al. (2006). v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med. 12, 1403-1409. https://doi.org/10.1038/nm1514
- Li, J., Sarosi, I., Yan, X.Q., Morony, S., Capparelli, C., Tan, H.L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U.S.A. 97, 1566-1571. https://doi.org/10.1073/pnas.97.4.1566
- Luchin, A., Suchting, S., Merson, T., Rosol, T.J., Hume, D.A., Cassady, A.I., and Ostrowski, M.C. (2001). Genetic and physical interactions between Microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J. Biol. Chem. 276, 36703-36710. https://doi.org/10.1074/jbc.M106418200
- Manolagas, S.C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137.
- Matsuo, K., Owens, J.M., Tonko, M., Elliott, C., Chambers, T.J., and Wagner, E.F. (2000). Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24, 184-187. https://doi.org/10.1038/72855
- Ogata, N., Chikazu, D., Kubota, N., Terauchi, Y., Tobe, K., Azuma, Y., Ohta, T., Kadowaki, T., Nakamura, K., and Kawaguchi, H. (2000). Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105, 935-943. https://doi.org/10.1172/JCI9017
- Oh, J.H., Lee, J.Y., Joung, S.H., Oh, Y.T., Kim, H.S., and Lee, N.K. (2015a). Insulin enhances RANKL-induced osteoclastogenesis via ERK1/2 activation and induction of NFATc1 and Atp6v0d2. Cell. Signal. 27, 2325-2331. https://doi.org/10.1016/j.cellsig.2015.09.002
- Oh, J.H., Lee, J.Y., Park, J.H., No, J.H., and Lee, N.K. (2015b). Obatoclax regulates the proliferation and fusion of osteoclast precursors through the inhibition of ERK activation by RANKL. Mol. Cells 38, 279-284. https://doi.org/10.14348/molcells.2015.2340
- Rodan, G.A. and Martin, T.J. (2000). Therapeutic approaches to bone diseases. Science 289, 1508-1514. https://doi.org/10.1126/science.289.5484.1508
- Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., and Martin, T.J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357. https://doi.org/10.1210/edrv.20.3.0367
- Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901. https://doi.org/10.1016/S1534-5807(02)00369-6
- Teitelbaum, S.L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1508. https://doi.org/10.1126/science.289.5484.1504
- Thrailkill, K.M., Lumpkin, C.K., Jr., Bunn, R.C., Kemp, S.F., and Fowlkes, J.L. (2005). Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am. J. Physiol. Endocrinol. Metab. 289, E735-745. https://doi.org/10.1152/ajpendo.00159.2005
- Vestergaard, P. (2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a metaanalysis. Osteoporos. Int. 18, 427-444. https://doi.org/10.1007/s00198-006-0253-4
- Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005). DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 202, 345-351. https://doi.org/10.1084/jem.20050645
- Yang, J., Zhang, X., Wang, W., and Liu, J. (2010). Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell. Biochem. Funct. 28, 334-341. https://doi.org/10.1002/cbf.1668
- Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602. https://doi.org/10.1073/pnas.95.7.3597
Cited by
- Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα vol.68, pp.2, 2019, https://doi.org/10.1007/s00011-018-1209-9
- The Regulation of p27Kip-1 and Bcl2 Expression Is Involved in the Decrease of Osteoclast Proliferation by A2B Adenosine Receptor Stimulation vol.23, pp.4, 2017, https://doi.org/10.15616/bsl.2017.23.4.327
- Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression vol.20, pp.15, 2017, https://doi.org/10.3390/ijms20153792
- Immune Complex–Driven Generation of Human Macrophages with Anti-Inflammatory and Growth-Promoting Activity vol.205, pp.1, 2020, https://doi.org/10.4049/jimmunol.1901382
- Endocrine role of bone in the regulation of energy metabolism vol.9, pp.1, 2017, https://doi.org/10.1038/s41413-021-00142-4